Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?
Recruiting
Phase 2
Interventional Study
Autoimmune Encephalitis (AE)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 40 (estimated)
- Sponsor
- University Hospital, Toulouse · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18-80 years;
* meeting clinical criteria for "possible" AE with identified antibodies;
* newly diagnosed with symptoms \<6 months;
* no second-line immunosuppressive treatment;
* high or mixed TSPO binding affinity phenotype.
Exclusion Criteria:
* Pregnant women;
* contr…
Contacts